VANCOUVER, British Columbia, October 07, 2021–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce that it entered into a non-binding letter of intent (“LOI“) dated October 5, 2021 to acquire a ketamine clinic (“Acquisition“) located in Richmond, Virginia (“Clinic“).

The Clinic was founded in 2019 and is an established practice managed by Dr. Randy Frederick, a board-certified Emergency Medicine physician and US Navy Veteran. The Clinic provides ketamine infusion treatments for many mood disorders, including depression, post-partum depression, bipolar depression, PTSD, OCD, and anxiety. They also treat chronic pain syndromes like chronic migraines, CRPS (formerly called RSD), fibromyalgia, phantom limb syndrome, trigeminal neuralgia and post-herpetic neuralgia. Since inception, the Clinic has provided over 1,500 infusions.

Under the contemplated Acquisition, Dr. Frederick will continue to manage the Clinic and utilize his medical license to open future clinics for the Company. The Clinic would be supported alongside the Company’s existing network of clinics, raising the profile of Revitalist’s brand and approach to patient care in the United States.

Pursuant to the terms of the LOI, the consideration contemplated for the Acquisition is estimated to be $1,000,000. The consideration is proposed to be payable as approximately $750,000 in common shares of Revitalist, $50,000 in cash, and the assumption of $250,000 in debt. The share consideration will be issued at the greater of $0.50/share and the 20-day volume weighted average share price preceding the issue date. The consideration shares will be issued 50% in 12 months and 50% in 24 months following the closing of the Acquisition.

Management Commentary

Kathryn Walker, CEO of Revitalist, commented: “We look forward to completing this Acquisition and utilizing Dr. Fredericks medical expertise to grow our business. We expect that the addition of Dr. Frederick will yield further expansion opportunities across the United States. This Acquisition fits perfectly within our strategy to grow our clinic footprint organically through a combination of build vs. buy. Dr. Frederick’s Clinic is the first of many established ketamine clinics that we intend to acquire and rebrand under the Revitalist platform.”

Dr. Randy Frederick, founder of the Richmond, Virginia Clinic, commented: “I am excited for the opportunity to bring my clinic and skillset to Revitalist. I plan on utilizing my experience in the US Navy, years of medical training, and knowledge of running a profitable ketamine clinic to facilitate Revitalist’s growth plans.”

*all figures expressed in Canadian dollars unless otherwise noted.

ABOUT REVITALIST LIFESTYLE AND WELLNESS

Revitalist Lifestyle and Wellness Ltd. is a publicly traded (CSE: CALM) (OTC: RVLWF) company, headquartered in Knoxville, Tennessee, with five clinics operating across the United States and expanding. Revitalist is dedicated to empowering individuals toward an improved quality of well-being through a combination of comprehensive care and future-centric treatments provided by medical professionals, mental health experts, and chronic pain specialists. Since opening their first clinic in 2018, Revitalist has provided over 7,000 infusions for patients suffering from treatment-resistant conditions. Additionally, Revitalist offers a number of lifestyle optimization services and vitamin infusions that can bring anyone closer to total wellness.

On Behalf of the Board
Kathryn Walker
Chief Executive Officer

For additional information and to be added to the Company’s mailing list, please click here.

Forward Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005847/en/

Contacts

Revitalist Lifestyle and Wellness Ltd.
Investor Relations
[email protected]
(865) 585-8414

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Unity Rd., a Cannabis Dispensary Franchise, Signs Agreements with Entrepreneurial Groups for Development in New Jersey and Virginia; Existing Partner Signs Lease in Maine for their First Unity Rd. Shop

PHOENIX, Sept. 23, 2021 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB) (the “Company”)—a vertically integrated, cannabis dispensary franchisor and operator that produces premium, award-winning products—today announced continued development of its cannabis dispensary franchise brand, Unity Rd., across the Northeastern United States. The industry trailblazer signed agreements for New Jersey and Virginia alongside continued expansion across the Northeast region:

– New Jersey – The New Jersey agreement was signed with an experienced entrepreneur whose familiarity with franchising drew him to the investment opportunity. Dish Patel and his business partner will join the strong list of three franchise groups that have signed with Unity Rd. to bring the brand to New Jersey – they’re all awaiting legislation to clear them for development.

– Virginia – As investors line up for the opportunity to bring Unity Rd.’s business model to their communities, Laurin Wallace, along with two business partners, signed on recently to bring a Unity Rd. to the Old Dominion state.

– Maine – Unity Rd. also supported their Maine franchise group in securing a lease and are now working with them on securing a dispensary license. This group was originally planning on developing in Massachusetts but pivoted to pursue opportunities in Maine to break into the burgeoning industry sooner. The state’s adult-use market launched in October 2020 and has been flourishing. This past August, it exceeded $10 million in sales for the first time in one month.

Learn more about Item 9 Labs Corp. and its cannabis franchise, Unity Rd., contact [email protected] or 800-403-1140, or visit https://investors.item9labscorp.com/.

Franchise Model Creates Low Corporate Capital Requirements for National Expansion

The Company acquired Unity Rd.’s parent company, OCG Inc., earlier this year, making it the first national, vertically integrated cannabis franchise company in the US. The combination of the Unity Rd. cannabis retail franchise and premium Item 9 Labs products puts Item 9 Labs Corp. in a unique industry position.

Item 9 Labs Corp.’s CEO Andrew Bowden, said “Unity Rd. franchise partners own and operate 100% of their businesses. Therefore, low corporate capital is required for national development of the brand, creating a capital-efficient method for both our retail and product expansion. By clustering our operations, we’re creating a focused network to more effectively launch the Unity Rd. and Item 9 Labs brands into new markets.”

Item 9 Labs Corp. plans to develop top tier cultivation and lab facilities all across the country as Unity Rd. franchises start to open – the first Unity Rd. franchise opened this past June in Boulder, Colorado. This strategic growth plan gives Unity Rd. operators front-of-the-line access to a reliable product supply chain and the Unity Rd. brand the national product consistency that consumers have come to expect from franchises. It also eases new market product entry with a built-in distribution platform that will bring Item 9 Labs across the nation.

Currently, Unity Rd. has multiple agreements signed with more than 15 entrepreneurial groups who are in various stages of development across eight states.

As a traditional franchise model, Unity Rd. franchise partners own 100% of their dispensary license and business, while benefitting from one of the safest routes for entrepreneurship in the complex, highly-regulated cannabis industry. The dispensary franchise’s time-tested Standard Operating Procedures (SOPs) and veteran team guide franchise partners through every operational function of the business, whether it be assisting with cash flow, product selection or the ever-changing regulations.

“The cannabis industry and all its complexities can be intimidating, leaving even the most capable of investors and operators unsure of where to start,” said Unity Rd.’s VP of Franchise Development Justin Livingston. “As part of the Unity Rd. network, our partners can operate their dispensaries more efficiently – resulting in more time to focus on growing the business rather than managing it. We’re offering the supportive network and tools they need to reach new heights and achieve their business goals.”

Franchise partners sign 10-year agreements and pay a $100,000 franchise fee up-front. The Company also earns a residual monthly 5% gross royalty on top-line revenue and a 2% marketing royalty fee per location.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

About Unity Rd.
Unity Rd. is bridging the two previously disconnected worlds of cannabis and franchising. The industry trailblazer is the first to bring the cannabis dispensary franchise model to the United States—with duality of prowess in both industries to back it up. Built up from a collective 200 years in the legal cannabis industry and franchising, the company helps eager operators enter the complex industry with ease. The marijuana franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Launched in 2018, Unity Rd. has signed multiple agreements with more than 15 entrepreneurial groups across the country. Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award. For more information, visit unityrd.com.

Media Contact:
Item 9 Labs
Jayne Levy, Director of Communications
Email: [email protected]

Investor Contact:
Item 9 Labs
800-403-1140
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Acquisition includes Dalitso’s 93,000 sq. ft. Facility and Nine Acres of Land

Positioned to Efficiently Produce a Consistent Supply of Medical Products as the Virginia Market Matures and Expands

Boca Raton, Florida – April 14, 2021 – Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), vertically integrated, multi-state cannabis operator, announced it signed a definitive agreement to purchase the 93,000 sq. ft. facility (the “Facility”), operated by its wholly-owned subsidiary and Virginia-based pharmaceutical processor, Dalitso LLC (“Dalitso”), together with approximately nine acres of surrounding land in Prince William County, Virginia, for approximately $22 million (the “Acquisition”). The Acquisition, together with Dalitso’s planned buildout of the Facility, will enable Dalitso to efficiently produce a consistent supply of medical cannabis products as patient access improves and as the medical cannabis program matures and expands. The Acquisition is subject to customary closing conditions and is expected to close in the second quarter of 2021.

“The Virginia cannabis market is an area of strategic focus for Jushi given Dalitso’s strong position in the most densely populated region in the Commonwealth,” said Jim Cacioppo, Chief Executive Officer, Chairman, and Founder of Jushi. “Through the completion of this acquisition, Dalitso will have the expansion capacity required to scale cultivation and processing to meet the anticipated patient demand of a growing program. Jushi is dedicated to providing patients with best-in-class products and dispensing experiences that go beyond expectations. To that end, we look forward to the continued build out of our Facility so we can best serve registered patients. Separately, we were pleased to see Governor Northam and the General Assembly respond to their constituents by moving the effective date of legal possession date for small amounts of cannabis forward to July 1, 2021. We hope the Governor and General Assembly will act expeditiously and with similar decisiveness to authorize legal procurement so Virginians without a medical certification have access to safe and controlled cannabis products in a regulated market without material delay.”

In December 2020, Jushi announced it completed the acquisition of the remaining 21% of the issued and outstanding equity of Dalitso, bringing its ownership to 100%. Jushi also announced in December 2020 that Dalitso had commenced operations at the Manassas facility and officially began serving patients at its BEYOND / HELLO Manassas location.

Dalitso is one of only five applicants to have received conditional approval for a pharmaceutical processor permit issued by the Virginia Board of Pharmacy, and one of only four to have received final approval and permit issuance in the Commonwealth. Dalitso’s permit allows Dalitso to cultivate, process, dispense, and deliver medical cannabis to registered patients in Virginia. The designated area for Dalitso to operate is Health Service Area II, in Northern Virginia, which includes two of Virginia’s most densely populated counties, Fairfax and Prince William, and has a population of approximately 2.5 million people or nearly 30% of the state’s total population according to the U.S. Census Bureau.

About Jushi Holdings Inc.

We are a vertically integrated cannabis company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis-derived assets through opportunistic acquisitions, distressed workouts, and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information, please visit jushico.com, twitter.com/wearejushi and beyond-hello.com.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, involve estimates, projections, plans, goals, forecasts, and assumptions that may prove to be inaccurate. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has certain expectations and has made certain assumptions. Expectations, assumptions, and risk factors are more fully described in the Company’s Management, Discussion and Analysis for the three months ended September 30, 2020, and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Not for distribution to United States newswire services or for dissemination in the United States.

For further information, please contact:

Investor Relations
Michael Perlman
Executive Vice President of Investor Relations and Treasury
[email protected]
(561) 281-0247

Media Contact
Ellen Mellody
MATTIO Communications
[email protected]
(570) 209-2947

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>